{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T11:35:39Z","timestamp":1760441739680,"version":"3.41.2"},"reference-count":47,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,8,10]],"date-time":"2022-08-10T00:00:00Z","timestamp":1660089600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>The aims of this study were to investigate the activation of T lymphocytes in peripheral blood from children with Hodgkin's lymphoma (HL) and explore their roles for prognosis in HL. A cohort of 52 newly diagnosed children with HL during the past 10 years was enrolled for analysis in this study. Peripheral blood samples of the patients were acquired before treatment in our hospital, and T-cell subsets were detected by a four-color flow cytometer. CD4+ T cells and CD4+\/CD8+ T-cell ratio decreased significantly in patients with HL vs. healthy controls. CD8+ T cells, CD3+CD4+HLA-DR+ T cells, and CD3+CD8+HLA-DR+ T cells increased markedly in patients with HL vs. healthy controls. Receiver-operating characteristic (ROC) curve analysis showed that CD3+CD4+HLA-DR+ T cells and CD3+CD8+HLA-DR+ T cells each distinguished the high-risk group from the low- and intermediate-risk group. The area under the ROC curve for predicting high-risk patients was 0.795 for CD3+CD4+HLA-DR+ T cell and 0.784 for CD3+CD8+HLA-DR+ T cell. A comparison of peripheral blood T-cell subsets that responded differently to therapy showed significantly higher percentages of CD3+CD4+HLA-DR+ T cells and CD3+CD8+HLA-DR+ T cells in patients who achieved complete remission compared to those who did not achieve complete remission. In addition, high percentages of both CD3+CD4+HLA-DR+ T cells and CD3+CD8+HLA-DR+ T cells were associated with inferior event-free survival. Peripheral immune status may be related to disease severity in HL. CD3+CD4+HLA-DR+ T cells and CD3+CD8+HLA-DR+ T cells may be a novel indicator for risk stratification of HL and may be an independent risk factor for inferior outcome in childhood HL.<\/jats:p>","DOI":"10.3389\/fmed.2022.955373","type":"journal-article","created":{"date-parts":[[2022,8,10]],"date-time":"2022-08-10T05:43:09Z","timestamp":1660110189000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["High percentages of peripheral blood T-cell activation in childhood Hodgkin's lymphoma are associated with inferior outcome"],"prefix":"10.3389","volume":"9","author":[{"given":"Fengqing","family":"Cai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhongsheng","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kun","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weizhong","family":"Gu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoping","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaojun","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongqiang","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiang","family":"Shu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,8,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/s13045-019-0785-7","article-title":"Burden of lymphoma in china, 2006-2016: an analysis of the global burden of disease study 2016","volume":"12","author":"Liu","year":"2019","journal-title":"J Hematol Oncol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1002\/pbc.24423","article-title":"Children's oncology group's 2013 blueprint for research: hodgkin lymphoma","volume":"60","author":"Kelly","year":"2013","journal-title":"Pediatr Blood Cancer"},{"key":"B3","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1097\/PPO.0000000000000345","article-title":"Lymphoma in adolescents and young adults: current perspectives","volume":"24","author":"Hochberg","year":"2018","journal-title":"Cancer J"},{"key":"B4","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1111\/bjh.13372","article-title":"Current approaches in the management of low risk Hodgkin lymphoma in children and adolescents","volume":"169","author":"Giulino-Roth","year":"2015","journal-title":"Br J Haematol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"e28562","DOI":"10.1002\/pbc.28562","article-title":"Pediatric classical Hodgkin lymphoma","volume":"68","author":"Lo","year":"2021","journal-title":"Pediatr Blood Cancer"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1182\/blood.2020010320","article-title":"Protect our children: Hodgkin lymphoma survivors","volume":"137","author":"Bartlett","year":"2021","journal-title":"Blood"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1038\/leu.2012.255","article-title":"Rituximab and FAB\/LMB 96 chemotherapy in children with Stage III\/IV B-cell non-Hodgkin lymphoma: a Children's Oncology Group report","volume":"27","author":"Goldman","year":"2013","journal-title":"Leukemia"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1080\/14656566.2019.1606212","article-title":"Treatment of classical Hodgkin's lymphoma in children and adolescents","volume":"20","author":"G\u00f3mez-Almaguer","year":"2019","journal-title":"Expert Opin Pharmacother."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1007\/s00247-019-04511-4","article-title":"Surveillance imaging in pediatric lymphoma","volume":"49","author":"Voss","year":"2019","journal-title":"Pediat Radiol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1111\/cas.14833","article-title":"Epstein-Barr virus latent membrane protein-1 upregulates autophagy and promotes viability in Hodgkin lymphoma: Implications for targeted therapy","volume":"112","author":"Lin","year":"2021","journal-title":"Cancer Sci"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1038\/s41591-020-1006-1","article-title":"A peripheral immune signature of responsiveness to PD-1 blockade in patients with classical Hodgkin lymphoma","volume":"26","author":"Cader","year":"2020","journal-title":"Nat Med"},{"key":"B12","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1007\/s10552-021-01446-w","article-title":"Long-term residential exposure to air pollution and Hodgkin lymphoma risk among adults in Denmark: a population-based case-control study","volume":"32","author":"Taj","year":"2021","journal-title":"Cancer Causes Control"},{"key":"B13","doi-asserted-by":"publisher","first-page":"2437","DOI":"10.1182\/blood.2020005546","article-title":"Rosetting T cells in Hodgkin lymphoma are activated by immunological synapse components HLA class II and CD58","volume":"136","author":"Veldman","year":"2020","journal-title":"Blood"},{"key":"B14","doi-asserted-by":"publisher","first-page":"352","DOI":"10.4132\/jptm.2017.03.15","article-title":"Epstein-barr virus-associated lymphoproliferative disorders: review and update on 2016 WHO classification","volume":"51","author":"Kim","year":"2017","journal-title":"J Pathol Transl Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.1182\/blood-2017-06-781989","article-title":"Signaling pathways and immune evasion mechanisms in classical Hodgkin lymphoma","volume":"130","author":"Liu","year":"2017","journal-title":"Blood"},{"key":"B16","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/nature22396","article-title":"PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity","volume":"545","author":"Gordon","year":"2017","journal-title":"Nature"},{"key":"B17","first-page":"539","article-title":"Coinhibitory Pathways in Immunotherapy for Cancer","volume-title":"Annual Review of Immunology, Vol 34","author":"Baumeister","year":"2016"},{"key":"B18","doi-asserted-by":"publisher","first-page":"e27307","DOI":"10.1002\/pbc.27307","article-title":"Flow cytometry for assessment of the tumor microenvironment in pediatric Hodgkin lymphoma","volume":"65","author":"Henry","year":"2018","journal-title":"Pediatr Blood Cancer"},{"key":"B19","doi-asserted-by":"publisher","first-page":"5300","DOI":"10.1182\/bloodadvances.2021004981","article-title":"Anti-CD25 radioimmunotherapy with BEAM autologous hematopoietic cell transplantation conditioning in Hodgkin lymphoma","volume":"5","author":"Herrera","year":"2021","journal-title":"Blood Adv"},{"key":"B20","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.3390\/ijms17122127","article-title":"Characterization of the Microenvironment of Nodular Lymphocyte Predominant Hodgkin Lymphoma","volume":"17","author":"Visser","year":"2016","journal-title":"Int J Mol Sci."},{"key":"B21","unstructured":"SwerdlowSH\n            CampoE\n            HarrisNL\n            JaffeES\n            PileriSA\n            SteinH\n          Lyon FranceInternational Agency for Research on CancerWHO Classification of Tumors of Haematopoietic Lymphoid Tissues. Edn. Revised 4th2017"},{"key":"B22","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/S1470-2045(03)01320-2","article-title":"Part II: Hodgkin's lymphoma\u2014diagnosis and treatment","volume":"5","author":"Diehl","year":"2004","journal-title":"Lancet Oncol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1002\/ajh.25071","article-title":"Hodgkin lymphoma: 2018 update on diagnosis, risk-stratification, and management","volume":"93","author":"Ansell","year":"2018","journal-title":"Am J Hematol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"v168","DOI":"10.1093\/annonc\/mdq181","article-title":"Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"21","author":"Engert","year":"2010","journal-title":"Annals Oncol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1055\/s-0035-1559664","article-title":"Pediatric nodular lymphocyte-predominant hodgkin lymphoma: treatment recommendations of the GPOH-HD study group","volume":"227","author":"Mauz-Korholz","year":"2015","journal-title":"Klin Padiatr"},{"key":"B26","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"415","DOI":"10.3390\/cancers10110415","article-title":"Profiling immune escape in Hodgkin's and diffuse large B-cell lymphomas using the transcriptome and immunostaining","volume":"10","author":"Pericart","year":"2018","journal-title":"Cancers"},{"key":"B28","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.pathol.2019.09.005","article-title":"Hodgkin lymphoma: a review of pathological features and recent advances in pathogenesis","volume":"52","author":"Piris","year":"2020","journal-title":"Pathology"},{"key":"B29","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.exphem.2007.01.030","article-title":"The relationships between Epstein-Barr virus latent membrane protein 1 and regulatory T cells in Hodgkin's lymphoma","volume":"35","author":"Marshall","year":"2007","journal-title":"Exp Hematol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1146\/annurev.immunol.16.1.471","article-title":"The origin of Hodgkin and Reed\/Sternberg cells in Hodgkin's disease","volume":"16","author":"K\u00fcppers","year":"1998","journal-title":"Annu Rev Immunol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"4069","DOI":"10.1182\/bloodadvances.2020002098","article-title":"The critical role of CD4+ T cells in PD-1 blockade against MHC-II-expressing tumors such as classic Hodgkin lymphoma","volume":"4","author":"Nagasaki","year":"2020","journal-title":"Blood Adv"},{"key":"B32","doi-asserted-by":"publisher","first-page":"2737","DOI":"10.3389\/fimmu.2018.02737","article-title":"CTLA-4 and PD-1 control of T-Cell motility and migration: implications for tumor immunotherapy","volume":"9","author":"Brunner-Weinzierl","year":"2018","journal-title":"Front Immunol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1200\/JCO.2017.77.3994","article-title":"Major histocompatibility complex class II and programmed death ligand 1 expression predict outcome after programmed death 1 blockade in classic Hodgkin lymphoma","volume":"36","author":"Roemer","year":"2018","journal-title":"J Clin Oncol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1182\/blood-2018-04-843714","article-title":"Mass cytometry of Hodgkin lymphoma reveals a CD4(+) regulatory T-cell-rich and exhausted T-effector microenvironment","volume":"132","author":"Cader","year":"2018","journal-title":"Blood"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1080\/10428194.2016.1239263","article-title":"The number of tumor infiltrating T-cell subsets in lymph nodes from patients with Hodgkin lymphoma is associated with the outcome after first line ABVD therapy","volume":"58","author":"Alonso-Alvarez","year":"2017","journal-title":"Leuk Lymphoma."},{"key":"B36","doi-asserted-by":"publisher","first-page":"2788","DOI":"10.3389\/fimmu.2018.02788","article-title":"Human CD8(+)HLA-DR(+) Regulatory T cells, similarly to classical CD4(+)Foxp3(+) cells, suppress immune responses via PD-1\/PD-L1 axis","volume":"9","author":"Machicote","year":"2018","journal-title":"Front Immunol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1097\/COC.0000000000000239","article-title":"CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition","volume":"39","author":"Buchbinder","year":"2016","journal-title":"Am J Clin Oncol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"794","DOI":"10.3324\/haematol.2015.132761","article-title":"The immune microenvironment in Hodgkin lymphoma: T cells, B cells, immune checkpoints","volume":"101","author":"Vardhana","year":"2016","journal-title":"Haematologica"},{"key":"B39","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/nature09754","article-title":"MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers","volume":"471","author":"Steidl","year":"2011","journal-title":"Nature"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1182\/bloodadvances.2017006346","article-title":"High proportions of PD-1(+) and PD-L1(+) leukocytes in classical Hodgkin lymphoma microenvironment are associated with inferior outcome","volume":"1","author":"Hollander","year":"2017","journal-title":"Blood Adv"},{"key":"B41","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.imlet.2004.10.005","article-title":"Can CD3+\/HLA-DR+ activated T cells predict the prognosis of non-Hodgkin's lymphoma patients?","volume":"97","author":"V\u00e1r\u00f3czy","year":"2005","journal-title":"Immunol Lett"},{"key":"B42","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/s00262-015-1791-4","article-title":"IL-6 down-regulates HLA class II expression and IL-12 production of human dendritic cells to impair activation of antigen-specific CD4(+) T cells","volume":"65","author":"Ohno","year":"2016","journal-title":"Cancer Immunol Immunother"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.1111\/cas.13332","article-title":"Interleukin-6\/STAT3 signaling as a promising target to improve the efficacy of cancer immunotherapy","volume":"108","author":"Kitamura","year":"2017","journal-title":"Cancer Sci"},{"key":"B44","doi-asserted-by":"publisher","first-page":"12281","DOI":"10.1073\/pnas.182618999","article-title":"STAT4 serine phosphorylation is critical for IL-12-induced IFN-gamma production but not for cell proliferation","volume":"99","author":"Morinobu","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B45","doi-asserted-by":"publisher","first-page":"3634","DOI":"10.3390\/cancers13143634","article-title":"Immune microenvironment features and dynamics in Hodgkin lymphoma","volume":"13","author":"Bertuzzi","year":"2021","journal-title":"Cancers (Basel)."},{"key":"B46","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.semcancer.2015.07.004","article-title":"Microenvironment abnormalities and lymphomagenesis: Immunological aspects","volume":"34","author":"Taylor","year":"2015","journal-title":"Semin Cancer Biol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"10813","DOI":"10.1038\/s41598-017-11052-z","article-title":"Cytotoxic response against Epstein Barr virus coexists with diffuse large B-cell lymphoma tolerogenic microenvironment: clinical features and survival impact","volume":"7","author":"Cohen","year":"2017","journal-title":"Sci Rep"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.955373\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,10]],"date-time":"2022-08-10T05:43:13Z","timestamp":1660110193000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.955373\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,10]]},"references-count":47,"alternative-id":["10.3389\/fmed.2022.955373"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2022.955373","relation":{},"ISSN":["2296-858X"],"issn-type":[{"type":"electronic","value":"2296-858X"}],"subject":[],"published":{"date-parts":[[2022,8,10]]},"article-number":"955373"}}